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A B S T R A C T
Background: Fatigue is a sensation of unbearable tiredness that frequently accompanies chronic widespread
musculoskeletal pain (CWP) and inﬂammatory joint disease. Its mechanisms are poorly understood and there is a
lack of eﬀective biomarkers for diagnosis and onset prediction. We studied the circulating metabolome in a
population sample characterised for CWP to identify biomarkers showing speciﬁcity for fatigue.
Material and methods: Untargeted metabolomic proﬁling was conducted on fasting plasma and serum samples of
1106 females with and without CWP from the TwinsUK cohort. Linear mixed-eﬀects models accounting for
covariates were used to determine relationships between fatigue and metabolites. Receiver operating curve
(ROC)-analysis was used to determine predictive value of metabolites for fatigue.
Results: While no association between fatigue and metabolites was identiﬁed in twins without CWP (n = 711),
in participants with CWP (n = 395), levels of eicosapentaenoate (EPA) ω-3 fatty acid were signiﬁcantly reduced
in those with fatigue (β=−0.452 ± 0.116; p = 1.2 × 10−4). A signiﬁcant association between fatigue and
two other metabolites also emerged when BMI was excluded from the model: 3-carboxy-4-methyl-5-propyl-2-
furanpropanoate (CMPF), and C-glycosyltryptophan (p = 1.5 × 10−4 and p = 3.1 × 10−4, respectively). ROC
analysis has identiﬁed a combination of 15 circulating metabolites with good predictive potential for fatigue in
CWP (AUC = 75%; 95% CI 69–80%).
Conclusion: The results of this agnostic metabolomics screening show that fatigue is metabolically distinct from
CWP, and is associated with a decrease in circulating levels of EPA. Our panel of circulating metabolites provides
the starting point for a diagnostic test for fatigue in CWP.
1. Introduction
Fatigue is a condition of debilitating tiredness, lethargy and lack of
energy which manifests as a symptom of many diﬀerent diseases and,
more rarely, on its own (chronic fatigue syndrome, CFS, also known as
myalgic encephalomyelitis, ME). The prevalence of fatigue may be as
high as 50% in the general population, though in most cases it is
transient and diminishes as the causal factor (e.g. viral infection) re-
solves [1,2]. Fatigue is a characteristic symptom of many chronic
rheumatic conditions such as rheumatoid arthritis (RA), system lupus
erythematous (SLE), and ﬁbromyalgia. Patients with SLE and RA report
persistent fatigue in up to 80–90% cases and there is no clear evidence
that it is related to disease activity [3–5]. Fatigue is also common in
non-inﬂammatory conditions such as cancer and neurological dis-
orders.
Fatigue is often associated with chronic pain; in rheumatic diseases
both the presence and the intensity of these symptoms are well corre-
lated [3,4,6,7]. In patients with RA and SLE painful symptoms such as
arthralgia are important contributing factors to fatigue severity; also,
pain has been shown to be the strongest predictor of fatigue in many
studies [4,8,9].
Fatigue often occurs in ﬁbromyalgia, a non-inﬂammatory condition
manifesting chronic widespread pain (CWP) accompanied by sleep
disturbance [10]. Due to the strong co-morbidity of ﬁbromyalgia and
chronic fatigue some researchers debate they are a single syndrome
caused by overlapping mechanisms [11]. This is supported by a genetic
epidemiology study that showed strong genetic correlation between
CWP and fatigue, suggestive of the presence of shared genes and mo-
lecular pathways [12]. On the other hand, other studies proposed that
co-occurrence between fatigue and CWP is due to their share of
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common psychiatric component (anxiety and depression) [13] which
also shares genetic determinants with CWP [12].
The metabolome comprises the sum of small molecule chemicals
(amino acids, lipids, fatty acids, sugars, vitamins, etc.) detectable in a
sample, usually serum, plasma or urine. It represents the higher end of
phenotypic expression of the genome and is, therefore, much closer to
the phenotype of interest than, say, protein expression. Metabolomic
studies are increasingly successful in identifying mechanisms of com-
plex diseases and may reveal new targets for therapy and provide di-
agnostic and prognostic tools [14–16].
We have recently demonstrated that individuals with CWP may
present with an altered metabolic proﬁle compared to healthy in-
dividuals [17]. It is also supported by the ﬁndings that the risk of CWP
increases with higher body mass index (BMI) [18]. Furthermore,
dietary risk factors which aﬀect metabolite levels, including higher
consumption of fats but lower consumption of fruit and vegetables,
have been found in those with CWP [18].
There are limited metabolome studies in fatigue [19–25] and no
studies have examined fatigue in the general population as opposed to a
clinical sample. We investigated the circulating metabolome in a large
sample of twins taken from the UK population. We were interested to
determine whether there is a pattern of circulating metabolome speciﬁc
for fatigue in people reporting CWP which might provide a diagnostic
biomarker for this symptom.
2. Material and methods
2.1. Sample
Participants were a sample of MZ and DZ twins enlisted in the
TwinsUK registry [26]. This is a bioresource which has been collected
and maintained by the Department of Twin Research and Genetic
Epidemiology at King's College London over the last 25 years. Ethical
approval is available from the St Thomas' Hospital Research Ethics
Committee and, at each visit, the participating twins provided fully
informed consent for their biological specimens, clinical and demo-
graphic information to be used in molecular epidemiology studies.
Many of the data including metabolome are available to internal and
external researchers subject to approval by the Twin Research Execu-
tive Committee (http://www.twinsuk.ac.uk/data-access/submission-
procedure/). Complete conﬁdentiality was assured and the twins
were unaware of any speciﬁc hypotheses.
An original sample for the current study comprised 4898 twins with
known status of CWP established as described elsewhere [17]. The
status of fatigue was assessed using three self-administered health
questionnaires collected in 2000, 2002 and 2008 (Supplementary
Table 1). Even though the deﬁnitions of fatigue using diﬀerent time
points (2000 vs 2002 and 2008) were not the same; the prevalence of
fatigue using deﬁnitions from questionnaires of 2000 and 2008 were
similar: 25.2% and 22.6%, respectively, and did not diﬀer statistically
(p = 0.494). Only two persons from 2002 were included in the ﬁnal
sample, both having no fatigue. Therefore, we analysed all the sample
together to increase the sample size and statistical power. Collection of
concomitant socio-demographic information and physical examination
was carried out during twin visits or via self-administered ques-
tionnaires. Each twin completed the questionnaires without reference
to co-twin and were unaware of the precise research hypothesis ad-
dressed in the study. Twins reporting inﬂammatory disease such as RA,
SLE and inﬂammatory bowel disease were excluded from the study.
2.2. Metabolome
Non-targeted metabolite detection and quantiﬁcation of 280 struc-
turally named biochemicals was conducted by the metabolomics pro-
vider Metabolon, Inc. (Durham, USA) on fasting plasma or serum
samples from the participants, as described previously [27]. Day
median normalization followed by inverse transformation of ranks to
normality was applied to the metabolites levels. Metabolite traits
with> 20% missing were excluded and missing values were imputed
to the day minimum. This produced 209 metabolites for the study. We
used both plasma and serum samples as they are highly correlated and
depend on the same genes [28]. However, we initially investigated
possible diﬀerences between the metabolomic proﬁles derived from
fasting serum and fasting plasma collected from the same twin volun-
teers. We have found that the results on plasma and serum were in
keeping with one another and elected, therefore, to increase the sample
size and hence the power by using both sample types. Moreover, we
adjusted for the specimen type in statistical analysis (see Statistical
analysis section). Throughout we refer to this plasma and serum me-
tabolome as the “circulating metabolome”.
2.3. C-reactive protein
C-reactive protein (CRP) levels from serum of twin volunteers were
established as described elsewhere [29]. The raw values of CRP were
normalized by inverse transformation of ranks prior to statistical ana-
lysis.
2.4. Statistical analysis
The statistical analysis was carried in three steps. First, risk factors
for fatigue were sought using univariate and multivariable mixed-ef-
fects regression including CWP, BMI and age, adjusting for family
structure and zygosity. Then, we assessed associations between fatigue
and metabolite levels using analysis of covariance (ANCOVA) by ﬁtting
linear mixed-eﬀects models with metabolites as dependant variables
and fatigue an independent factor, also adjusting for age, BMI, biolo-
gical specimen type (plasma or serum) and processing batch, family
structure and zygosity. Mediation analysis stratifying for presence/ab-
sence of CWP was carried out to determine if BMI was a mediator of the
eﬀects of fatigue on the levels of metabolites. Statistical signiﬁcance
threshold was set at p < 0.0005 corresponding to 100 independent
tests with Bonferroni correction. The number of independent tests was
estimated using the correlation structure of the observed metabolites in
the TwinsUK dataset [30]. Finally, we assessed predictive capacity of
the circulating metabolome for fatigue using ROC-analysis. Association
between CRP levels and fatigue was assessed using ANCOVA in the
same way as for the metabolites. Adjustment was made for age, BMI,
family structure and zygosity. All analyses were performed in R using
basic functions and packages “lme4” [31], “mediation” [32] and
“PredictABEL” [33].
3. Results
3.1. The prevalence and risk factors for fatigue
A total sample of 4898 twins from the TwinsUK dataset has been
assessed for fatigue using postal questionnaires. Complete covariate
data were available for 2055 female individuals, which have been
analysed further. In this sample, the prevalence of fatigue was 22.3%
(Table 1) with much higher frequency in individuals with CWP as
compared to those without CWP (38.6 vs 15.2%, p = 2.2 × 10−16).
Both in the CWP group and in non-CWP group, fatigue was asso-
ciated with the increased BMI: 28.7 ± 6.4 vs 26.7 ± 4.9 kgm−2
(p = 3.9 × 10−5) in individuals with CWP and 26.2 ± 5.2 vs
25.4 ± 4.8 kgm−2 (p = 0.030) in those without CWP, respectively.
Also, females with fatigue were younger that those without it, though it
was only marginally statistically signiﬁcant in the non-CWP group:
57.7 ± 11.1 vs 60.8 ± 10.2 years (p = 5 × 10−4) with CWP and
50.4 ± 15.5 vs 52.5 ± 14.8 years (p = 0.060) in those without CWP.
CWP was signiﬁcantly associated with fatigue independent of BMI
and age (Table 2) as it remained highly statistically signiﬁcant with
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similar eﬀect size after including these risk factors in the regression
model. The eﬀects of BMI and age were also statistically signiﬁcant in a
multivariable model including CWP, though their eﬀects decreased
suggesting some collinearity between CWP and age and BMI (Table 2).
Mediation analysis showed that 6% of the total eﬀect of CWP on the
risk of fatigue is mediated via BMI (p = 0.0002), while the estimated
mediation eﬀect of CWP exceeded total and direct eﬀects of BMI on the
risk of fatigue, suggesting that the eﬀect of BMI is not independent of
the eﬀect of CWP. The results show that CWP is a strong and in-
dependent risk factor for fatigue, while BMI is secondary to CWP as a
risk factor of fatigue. Taking this into account, the subsequent analysis
of association between the circulating metabolites and fatigue was
carried out in groups stratiﬁed by the presence of CWP.
3.2. Association between fatigue and the circulating metabolome
A total of 209 circulating metabolites were tested for association
with fatigue in 1106 twin females stratiﬁed by the presence of CWP
(fatigue diagnosed in 114 out of 395 twins with CWP and in 93 out of
711 twins without CWP). In the non-CWP group, no statistically sig-
niﬁcant associations of fatigue and the metabolites was found after
adjustment for multiple testing (Supplementary Table 2). In the CWP
group, essential fatty acid eicosapentaenoate (EPA) was found to be
associated with fatigue, being signiﬁcantly decreased in cases
(β=−0.452 ± 0.116; p = 1.2 × 10−4; Fig. 1; Supplementary
Table 3).
Exclusion of BMI from the regression model showed the association
with EPA to remain statistically signiﬁcant with similar eﬀect size
(β=−0.480 ± 0.115; p = 3.9 × 10−5) and two other metabolites
also reached statistical signiﬁcance for association with fatigue: 3-car-
boxy-4-methyl-5-propyl-2-furanpropanoate lipid (CMPF), and C-glyco-
syltryptophan amino acid (β=−0.406 ± 0.106; p = 1.5 × 10−4
and β= 0.390 ± 0.107; p = 3.1 × 10−4, respectively) (Fig. 1; Sup-
plementary Table 3).
Mediation analysis for EPA, CMPF, and C-glycosyltryptophan was
carried out based on the assumption that BMI may mediate the eﬀects
of fatigue. A statistically signiﬁcant mediation eﬀect of BMI was es-
tablished for CMPF and C-glycosyltryptophan, but not for EPA
(Table 3). Mediation eﬀect relative to the total eﬀect was 13% and 25%
for CMPF and C-glycosyltryptophan, respectively.
Table 1
Demographics of females from the TwinsUK dataset assessed for the presence of fatigue.
Subgroup Prevalence of
fatigue, %
Age (± SD), years BMI (± SD), kg/m2
Total sample,
n = 2055
22.3 54.4 ± 14.2 26.1 ± 5.2
With CWP,
n = 621
38.6 59.6 ± 10.7 27.4 ± 5.6
Without CWP,
n = 1434
15.2 52.2 ± 14.9 25.5 ± 4.9
CWP, chronic widespread pain.
Table 2
The eﬀect of CWP on the risk of fatigue.
Model Factor Eﬀect (β) SE p-Value
Univariate CWP 1.288 0.112 6.0e–26
Multivariable CWP 1.319 0.131 5.7e–24
BMI 0.051 0.011 7.6e–6
Age −0.016 0.005 6.5e–4
Logistic regression analysis of the dependence between fatigue and CWP adjusting for
family structure and zygosity.
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3.3. Association between fatigue and serum C-reactive protein
To check if fatigue was associated with occult inﬂammation, we
analysed serum levels of CRP in groups stratiﬁed by fatigue and CWP.
Using ANCOVA with adjustment for covariates, the levels of CRP were
found to be statistically signiﬁcantly increased in females with fatigue
in the CWP group, but not the non-CWP group (β= 0.189 ± 0.083;
p = 0.023 and β= 0.133 ± 0.084; p = 0.112, respectively).
3.4. Predictive capacity of the circulating metabolome for fatigue
Regression models were ﬁtted with predictors comprising all pos-
sible combinations (pairs, threes, fours, etc.) of metabolites for which p-
value was< 0.25 for association with fatigue in females with CWP.
Best ﬁt models for each combination sets were chosen based on Akaike
Information Criterion followed by the ROC-analysis to check their
predictive capacity for fatigue in CWP. The highest accuracy was
achieved with a combination of 15 circulating metabolites, giving area
under curve (AUC) = 0.746 [95% CI: 0.693–0.798], with the cross-
validation error equal to 0.19 as established by jack-knife resampling
(Table 4; Fig. 2). We additionally checked the performance of the model
using twin pairs discordant for fatigue from the CWP group. Overall,
there were 16 such the pairs in the dataset including 8 MZ and 8 DZ.
Risks of fatigue were estimated using the predictive model and com-
pared with known fatigue status of the twins. The prediction accuracies
were 68.8% (95% CI 41.3%–89.0%, p = 0.105) for the MZ twins and
50.0% (28.2%–71.8%, p = 0.584) for the DZ twins.
4. Discussion
This is the ﬁrst population study of fatigue in CWP using metabo-
lomics screening. We found fatigue associated with lower circulating
levels of the eicosapentaenoate (EPA) ω-3 fatty acid in those with CWP.
No association between EPA levels and CWP itself were seen either in
the current study or in our earlier metabolome investigation of CWP
alone [17]. This suggests that the decrease of EPA is a characteristic
metabolic feature of CWP-associated fatigue and may serve as a bio-
marker for this condition. It further suggests that CWP and fatigue do
Table 3
Direct and BMI-mediated eﬀects of fatigue on circulating metabolite levels.
Metabolite Eﬀect of fatigue mediated via BMI
(mediation eﬀect)
Direct eﬀect of fatigue accounting for
mediation eﬀect of BMI
Total eﬀect (summary of mediated
and direct eﬀects)
Proportion of the total eﬀect
attributable to mediation eﬀect
EPA −0.01
[−0.03;0.008]
p = 0.27
−0.16
[−0.26;−0.07]
p < 0.001
−0.17
[−0.27;−0.08]
p < 0.001
0.06
[−0.05;0.24]
p = 0.27
CMPF −0.02
[−0.05;−0.001]
p = 0.04
−0.15
[−0.26;−0.03]
p = 0.01
−0.17
[−0.28;−0.06]
p < 0.001
0.13
[0.005;0.47]
p = 0.05
C-glycosyltryptophan 0.05
[0.02;0.09]
p < 0.001
0.15
[0.04;0.26]
p = 0.01
0.20
[0.09;0.31]
p < 0.001
0.25
[0.10;0.62]
p < 0.001
Mediation analysis to reveal the eﬀect of fatigue on EPA levels mediated via BMI.
Table 4
Circulating metabolites for the best predictive model for fatigue in CWP.
Metabolon_ID Biochemical Pathway Sub-pathway Level in fatigue
M18476 glycocholate Lipid Bile acid metabolism Increased
M15500 carnitine Lipid Carnitine metabolism Decreased
M01105 linoleate (18:2n6) Lipid Essential fatty acid Decreased
M31787 3-carboxy-4-methyl-5-propyl-2-furanpropanoate (CMPF) Lipid Fatty acid/dicarboxylate Decreased
M27722 erythrose Carbohydrate Fructose/mannose/galactose/starch/and sucrose metabolism Increased
M20489 glucose Carbohydrate Glycolysis/gluconeogenesis/pyruvate metabolism Increased
M00059 histidine Amino acid Histidine metabolism Decreased
M12067 undecanoate (11:0) Lipid Medium chain fatty acid Decreased
M21188 1-stearoylglycerol (1-monostearin) Lipid Monoacylglycerol Increased
M32197 3-(4-hydroxyphenyl)lactate Amino acid Phenylalanine & tyrosine metabolism Decreased
M35126 phenylacetylglutamine Amino acid Phenylalanine & tyrosine metabolism Increased
M22130 phenyllactate (PLA) Amino acid Phenylalanine & tyrosine metabolism Increased
M32675 C-glycosyltryptophan Amino acid Tryptophan metabolism Increased
M35431 2-methylbutyroylcarnitine Amino acid Valine/leucine and isoleucine metabolism Increased
M22116 4-methyl-2-oxopentanoate Amino acid Valine/leucine and isoleucine metabolism Decreased
Fig. 2. ROC plot for prediction of fatigue in CWP using 15 circulating metabolites. A
combination of the metabolites was selected from all possible combinations (two, three,
four, etc.) by choosing the best predictive model as detailed in the main text (Table 4).
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not fully overlap metabolically and do, therefore, represent distinct
physiological syndromes. Our results are concordant with previous
ﬁndings of EPA level decrease in patients with ME/CFS that suggested
that ω-3 fatty acid availability is linked to immune pathophysiology of
the syndrome [34].
EPA is known to exhibit anti-inﬂammatory eﬀects through a variety
of mechanisms including decreased production of chemoattractants,
down-regulation of NFκB, production of eicosanoids competing with
pro-inﬂammatory molecules and other processes [35]. At the same
time, inﬂammatory model of chronic fatigue is one of the most widely
accepted; pro-inﬂammatory cytokines originating from systemic or
peripheral inﬂammation act on the brain and initiate so called sickness
behaviour characterised by loss of appetite, sleepiness, decreased social
activity, depression and fatigue [36,37]. Hypothetically, the decrease of
EPA levels may result in the downregulation of anti-inﬂammatory
pathways and promote the development of fatigue. This is additionally
supported by the observed elevated serum levels of C-reactive protein
in people reporting fatigue in the CWP group.
Given that the reduced EPA levels found in our study were unique to
individuals with CWP and fatigue combined, it suggests there may be
notable diﬀerences between fatigue in individuals with CWP in com-
parison to people who present with fatigue alone. Among the metabo-
lites that were found at least nominally statistically signiﬁcantly asso-
ciated with fatigue in the non-CWP group, the top ones were amino-
acids 2-hydroxyisobutyrate, glutamate, N-acetylthreonine, and 3-me-
thylhistidine, and a peptide gamma-glutamylvaline (Supplementary
Table 2). This suggests that fatigue reported by the non-CWP group may
rather be related to muscle fatigue and wasting [38], and thus is in-
trinsically distinct from fatigue reported by the CWP group.
Apart from EPA, other essential fatty acids, such as doc-
osapentaenoate (DPA) and docosahexaenoate (DHA) were decreased in
fatigue in CWP group, though these did not reach the statistical sig-
niﬁcance threshold (Supplementary Table 3). All these metabolites
occur in the body via dietary routes; either via direct consumption of ω-
3 containing foods (e.g. ﬁsh or ﬁsh oils) or via the dietary precursor
alpha-linolenic acid [39]. There are a number of reasons why low EPA
levels may be seen in individuals at risk of fatigue in CWP. One of these
may be signiﬁcant dietary diﬀerences between those with CWP and
controls. Individuals with CWP more likely to have a diet high in fat
and low in fruit and vegetables [18]; this type of “Western” style diet
has been found to be low in ω-3 fatty acids (reﬂected in low con-
sumption of ﬁsh, fruit and vegetables) despite high amounts of satu-
rated fats [40]. It is unknown as to why such dietary diﬀerences are
found in individuals with CWP, although it can be hypothesised that it
may be related to common comorbid factors such as a depressive mood
state, which may lead to greater consumption of high fat foods which
induce a pleasurable mood state during or shortly after consumption
[41]. A reduction in dietary quality below some critical level could
feasibly lead to further ill health due to a lack of nutrients, including
low levels of EPA.
This raises a question of “healthy/normal” levels of EPA and other
essential fatty acids. At present, despite a growing scientiﬁc literature
devoted to supplementation in various states of ill health, the normal
range of circulating EPA is yet to be agreed [42]. Given that TwinsUK is
known to be representative of a general population [26], the levels ofω-3
fatty acids measured in our sample could serve as a normal baseline for
Northern Europeans of a respective age group. Unfortunately, the Me-
tabolon platform used in the current study do not allow absolute quan-
tiﬁcation of the metabolites; therefore, we cannot provide such values in
our sample from TwinsUK. However, the absolute levels of ω-3 fatty
acids were reported for about 900 generally healthy middle age and el-
derly women from the same TwinsUK resource using another platform:
DHA 0.14 ± 0.05 mmol/L; EPA + DHA 0.44 ± 0.14 mmol/L [43].
In the CWP group, we also observed an association between fatigue
and CMPF and C-glycosyltryptophan with a signiﬁcant mediation eﬀect
of BMI. To the best of our knowledge, none of these metabolites are
currently known to be related to chronic pain or fatigue, though C-
glycosyltryptophan is associated with aging and age-related traits [27]
and CMPF is related to chronic renal failure and renal cell damage [44].
Thus, these metabolites may be considered as new biomarkers of fa-
tigue in CWP and their study may improve our understanding of the
nature of this condition.
We identiﬁed a set of 15 circulating metabolites that may provide a
relatively strong biomarker of fatigue in CWP (AUC 0.746 [95% CI:
0.693–0.798]). Taking advantage of powerful discordant twin-pairs
design, the accuracy of the model was estimated to be 68.8% for MZ
twins and 50.0% for DZ twins. These estimates were obtained in a very
limited sample (8 pairs of twins in each group), therefore must be
treated with caution. As fatigue associated with CWP may be a mani-
festation of CFS, using this biomarker tool may be able to provide a
diagnostic of this syndrome and help diﬀerentiate CWP and CFS. A
recent targeted metabolome study of CFS/ME produced a very accurate
classiﬁer with AUC estimates equal to 94%–96% [22]. There are several
reasons for the lower accuracy of our panel. First, we did not deal with
clinically proven diagnosis of ME/CFS, rather with the self-reported
fatigue, thus resulting in a higher heterogeneity of our sample. Second,
we contrasted fatigue vs non-fatigue in a speciﬁc context – among
people with CWP – so the diagnostic accuracy may decrease as CWP
itself is characterised by a speciﬁc metabolic proﬁle [17] and shares
pathogenetic links with fatigue [11].
To date, metabolomic studies of fatigue are limited to animal
models and clinical samples. In patients with RA, increasing fatigue
scores were associated with a metabolic pattern characterised by down-
regulation of metabolites from the urea cycle, fatty acids, tocopherols,
aromatic amino acids, and hypoxanthine [24]. Urine metabolome stu-
dies showed a signiﬁcant correlation between aminohydroxy-N-me-
thylpyrrolidine and beta-alanine with CFS expression [20,21]. In a rat
model of fatigue, distinctive changes in plasma metabolites related to
branched-chain amino acid metabolism, urea cycle, and proline meta-
bolism in the fatigued group were discovered [19]. The most recent
clinical study of 612 plasma metabolites identiﬁed abnormalities in 20
metabolic pathways associated with CFS [22].
Our study has several limitations. We analysed only females, so
results are not applicable to males. Another limitation is the use of
questionnaires obtained over diﬀerent years with various deﬁnitions of
fatigue. However, there was no diﬀerence in fatigue prevalence be-
tween diﬀerent deﬁnitions; also, the prevalence of fatigue in our
sample, 22.3%, is close the ﬁgure of 20.9% obtained in a similar po-
pulation study of Swedish twins [45]. Also, the association between
EPA levels and fatigue was only established in participants with CWP,
thus this ﬁnding cannot be generalized to fatigue associated with other
conditions. The study of Swedish twins identiﬁed several sub-classes of
fatigue each characterised by a combination of such symptoms as im-
pairment, memory deterioration, sore throat, tender lymph nodes,
muscle pain, multi-joint pain, headache, unrefreshing sleep, and post-
exertional malaise [45]. This suggests that fatigue should be considered
as a heterogeneous condition. We have not sub-classiﬁed fatigue in our
study, but this would be a reasonable next step. Finally, given the cross-
sectional design of the current study, all proposed mechanistic links
remain speculative and require testing in a randomized controlled study
or using instrumental analysis such as Mendelian randomization [46].
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.bbadis.2017.11.025.
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